Commissioner Succession Plan? Abernethy As Gottlieb’s Number Two Offers One Option

Gottlieb’s choice of Amy Abernethy as US FDA principal deputy could set her up to succeed him, should the need arise. CDER’s Cavazzoni will fill the post on temporary basis, elevating her profile within agency.

FDAEntrance_1200x675

US FDA Commissioner Scott Gottlieb’s choice of Flatiron Health Inc. executive Amy Abernethy as his principal deputy commissioner to success a retiring Rachel Sherman offers one potential succession plan, should he decide to eventually leave the agency.

In Abernethy, Gottlieb brings to FDA an individual whose background neatly overlaps with much of the agency’s leadership over the past two decades

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Restoring Some Library Resources

 

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

US FDA Advisory Committee Misperceptions Abound … At HHS

 

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.

US FDA Layoffs Hit Conflict-Of-Interest Screening For ODAC Meeting

 

Screening for conflicts and finding the right expertise for a two-day Oncologic Drugs Advisory Committee meeting on four products has been complicated by the Trump Administration’s initial communications freeze and subsequent layoffs in CDER.

More from Agency Leadership